Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

PNR Accepted - Flucelvax


Our STN: 125408/0                                                                          
Novartis Vaccines and Diagnostics, Inc.
Attention: Matthew Gollwitzer
350 Massachusetts Avenue
Cambridge, MA 02139
Dear Mr. Gollwitzer:
We have reviewed your submission dated June 28, 2012, to your biologics license application (BLA) for Influenza Vaccine (MDCK Cells) requesting a proprietary name review. 
In consultation with CBER’s Advertising and Promotional Labeling Branch (APLB), we conclude that your proposed proprietary name, Flucelvax, is acceptable under the Federal Food, Drug, and Cosmetic Act and applicable regulations. Your alternate proposed proprietary name,      --(b)(4)--, is unacceptable because of the potential medication errors with penicillin antibiotics.
If you have any questions, please contact Dr. Brenda Baldwin or Dr. Timothy Fritz at (301) 796-2640.
Sincerely yours,
Wellington Sun, M.D.
Division of Vaccines and
 Related Products Applications
Office of Vaccine
 Research and Review
Center for Biologics
Evaluation and Research

Page Last Updated: 12/19/2012
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English